Response and Amendment under 37 CFR § 1.111

SEP, 2 6 2006

Application No. 10/622,76951

Page 2 of 8

Amendments to Claims

This listing of claims will eplace all for versions, and listings, of claims in the application.

## **Listing of Claims:**

- 1. (Canceled)
- 2. (Canceled)
- 3. (Currently Amended) A method for treating severe Alzheimer's dementia in a patient in need thereof comprising administering 3.0 mg to 10.0 mg of donepezil 1-benzyl-4-(5,6-dimethoxy-1-indanon)2-yl)methylpiperidine or a pharmaceutically acceptable salt thereof to treat severe Alzheimer's dementia in the patient; wherein severe Alzheimer's dementia is characterized by a score of 5 to 9 on the Mini-Mental State Examination.
- 4. (Currently Amended) A method for treating severe Alzheimer's dementia in a patient in need thereof comprising administering 10 mg of <u>donepezil 1-benzyl-4 (5,6-dimethoxyl-indanon)2-yl)methylpiperidine</u> hydrochloride to treat severe Alzheimer's dementia in the patient; wherein severe Alzheimer's dementia is characterized by a score of 5 to 9 on the Mini-Mental State Examination.
- 5. (Currently Amended) A method for treating severe Alzheimer's dementia in a patient in need thereof comprising administering a therapeutically effective amount of <u>donepezil 1-benzyl-4-(5,6-dimethoxy-1-indanon)2-yl)methylpiperidine</u> or a pharmaceutically acceptable salt thereof to treat severe Alzheimer's dementia in the patient; <u>wherein severe Alzheimer's dementia is characterized</u> by a score of 5 to 9 on the Mini-Mental State Examination.
- 6. (Currently Amended) The method of claim 5, comprising administering 0.3 mg to 50 mg of donepezil 1-benzyl-4-(5,6-dimethoxy-1-indanon)2-yl)methylpiperidine or a pharmaceutically acceptable salt thereof to treat severe Alzheimer's dementia in the patient.
- 7. (Currently Amended) The method of claim 6, comprising administering 3.0 mg to 10.0 mg of donepezil 1-benzyl-4-(5,6-dimethoxy-1-indanon)2-yl)methylpiperidine or a pharmaceutically acceptable salt thereof to treat severe Alzheimer's dementia in the patient.
  - 8. (Canceled)
  - 9. (Canceled)
- 10. (New) The method of claim 3, comprising administering donepezil hydrochloride.

Response and Amendment under 37 CFR § 1.111 Application No. 10/622,769 Page 3 of 8

- 11. (New) The method of claim 3, comprising administering 5 mg of donepezil or a pharmaceutically acceptable salt thereof.
- 12. (New) The method of claim 3, comprising administering 10 mg of donepezil or a pharmaceutically acceptable salt thereof.
- 13. (New) The method of claim 3, comprising administering 5 mg of donepezil hydrochloride to the patient daily for a period of 4 weeks and then administering 10 mg of donepezil hydrochloride to the patient daily.
- 14. (New) The method of claim 3, wherein the method for treating severe Alzheimer's dementia results in an improvement in the patient's score on the Mini-Mental State Examination.
- 15. (New) The method of claim 3, wherein the method for treating severe Alzheimer's dementia results in no change in the patient's score on the Mini-Mental State Examination.
- 16. (New) The method of claim 4, wherein the method for treating severe Alzheimer's dementia results in an improvement in the patient's score on the Mini-Mental State Examination.
- 17. (New) The method of claim 4, wherein the method for treating severe Alzheimer's dementia results in no change in the patient's score on the Mini-Mental State Examination.
- 18. (New) The method of claim 5, comprising administering donepezil hydrochloride.
- 19. (New) The method of claim 5, comprising administering 0.5 mg to 10 mg of donepezil or a pharmaceutically acceptable salt thereof.
- 20. (New) The method of claim 5, comprising administering 5 mg of donepezil or a pharmaceutically acceptable salt thereof
- 21. (New) The method of claim 5, comprising administering 10 mg of donepezil or a pharmaceutically acceptable salt thereof.
- 22. (New) The method of claim 3, wherein the method for treating severe Alzheimer's dementia results in an improvement in the patient's score on the Mini-Mental State Examination.

Response and Amendment under 37 CFR § 1.111 Application No. 10/622,769 Page 4 of 8

23. (New) The method of claim 3, wherein the method for treating severe Alzheimer's dementia results in no change in the patient's score on the Mini-Mental State Examination.